Annexon Announced Topline Results From A Real-world Evidence Study Supporting Anx005 As A Potential Treatment For Guillain-barré Syndrome
Annexon Announced Topline Results From A Real-world Evidence Study Supporting Anx005 As A Potential Treatment For Guillain-barré Syndrome
Annexon宣布了一项真实世界证据研究的顶线结果，支持Anx005作为吉兰-巴雷综合征的潜在治疗方案。
- Real-World Evidence Study Strengthens the Body of Evidence Supporting ANX005 for Treatment of GBS
- ANX005 Phase 3 Population Was Matched 1:1 on Prespecified Criteria with Patients in International GBS Outcomes Study (IGOS)
- Matched Cohort Study Showed Early and Greater Benefits of ANX005 over IVIg or PE in Muscle Strength and Functional Outcomes Across Multiple Measurements
- 现实世界的证据研究强化了支持 ANX005 治疗 GBS 的大量证据
- 根据预先设定的标准，ANX005 三期人群与国际 GBS 结局研究 (IGOS) 中的患者以 1:1 的比例匹配
- 匹配的队列研究显示，在多次测量中，ANX005 在肌肉力量和功能结果方面比 iViG 或 PE 具有更大的早期益处